Latest SMC decisions

The Scottish Medicines Consortium (SMC) has issued its latest set of assessments.

The COPD treatment aclidinium bromide (Eklira Genuair) is amongst the latest medicines approved for use in NHS Scotland.
The COPD treatment aclidinium bromide (Eklira Genuair) is amongst the latest medicines approved for use in NHS Scotland.

Medicines approved for use within NHS Scotland are as follows:

  • Aclidinium bromide (Eklira Genuair), for maintenance bronchodilator treatment in adults with chronic obstructive pulmonary disease
  • Colecalciferol (Fultium D3), for the prevention and treatment of vitamin D deficiency and as an adjunct in osteoporosis
  • Fluticasone/formoterol (Flutiform), for the regular treatment of asthma where the combination of a long-acting β2-agonist and an inhaled corticosteroid is appropriate
  • Mercaptopurine (Xaluprine) oral solution, for the treatment of acute lymphoblastic leukaemia
  • Nepafenac (Nevanac), to reduce the risk of postoperative macular oedema associated with cataract surgery in diabetic patients
  • Velaglucerase (Vpriv), for long-term enzyme replacement therapy in type 1 Gaucher disease.

The following are accepted for restricted use:

  • Abiraterone (Zytiga), for use in combination with prednisolone after failure of docetaxel-based chemotherapy in patients with metastatic-castration-resistant prostate cancer who have received only one prior chemotherapy regimen
  • Fingolimod (Gilenya), as a single disease-modifying therapy in highly active relapsing remitting multiple sclerosis (MS) in adults with high disease activity despite treatment with  beta-interferon, who have an unchanged or increased relapse rate compared with the previous year, or ongoing severe relapses
  • Ivabradine (Procoralan), in combination with standard therapy including β-blockers or when β-blockers are contraindicated/not tolerated, for NHYA class II–IV heart failure with systolic dysfunction in patients who are in sinus rhythm and whose resting heart rate remains 75 beats per minute or more despite optimal standard therapy
  • Tegafur/gimeracil/oteracil (Teysuno), for use in patients with advanced gastric cancer who are unsuitable for the first-line regimen of an anthracycline, fluorouracil and platinum;
  • Tocilizumab (RoActemra), for use in accordance with British Society for Rheumatology guidance on prescribing TNF blockers in adults with rheumatoid arthritis.

Several medicines were rejected:

  • Adalimumab (Humira), for moderate to severe active ulcerative colitis
  • Amifampridine (Firdapse), for Lambert-Eaton myasthenic syndrome
  • Argatroban (Exembol), indicated in heparin-induced thrombocytopenia type II
  • Azilsartan medoxomil (Edarbi), used to treat essential hypertension
  • Azithromycin (Azyter) for antibacterial conjunctivitis
  • Bevacizumab (Avastin), for epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • Caffeine citrate (Peyona), for primary apnoea in premature newborns
  • Interferon beta-1a (Rebif), in patients at high risk of developing MS
  • Pasireotide (Signifor), for Cushing’s disease
  • Ranolazine (Ranexa), as an add-on therapy for the symptomatic treatment of stable angina pectoris
  • Rifaximin (Xifaxanta), for travellers’ diarrhoea
  • Strontium ranelate (Protelos), in the treatment of osteoporosis in men
  • Tocofersolan (Vedrop), for children with vitamin E deficiency
  • Vemurafenib (Zelboraf), a treatment for metastatic melanoma
  • Zonisamide (Zonegran), for partial seizures in epilepsy.

Further information: Scottish Medicines Consortium

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more